ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

$24 million slated for Parkinson’s research

by Lisa M. Jarvis
February 5, 2018 | APPEARED IN VOLUME 96, ISSUE 6

The Michael J. Fox Foundation, NIH, and five life sciences companies—Celgene, GlaxoSmithKline, Pfizer, Sanofi, and Verily Life Sciences—have launched a public-private partnership aimed at understanding the molecular underpinnings of Parkinson’s disease. The partners have jointly committed $24 million to the project, which is part of NIH’s Accelerating Medicines Partnership. The first goal of the partnership is to analyze existing data and patient samples for biomarkers that allow the disease to be measured, tracked, and ultimately, treated.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment